EOLO PHARMA Announces Regulatory Clearance To Initiate Phase 1 Study Of MVD1 For Obesity And Type 2 Diabetes
19 de May de 2023
No Comments
EOLO PHARMA announced that it has received approval to initiate a Phase 1 clinical trial for MVD1, the company’s investigational small molecule designed to reduce
EOLO PHARMA announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and its cardiometabolic complications.
18 de May de 2023
No Comments
EOLO PHARMA today announced that it has dosed the first subjects in Phase 1 clinical trials of MVD1, designed to prevent and treat obesity and
Follow Us On